Immunic AG | WebDisclosure

PRESS RELEASE

published on 09/04/2024 at 12:30, 2 months 17 days ago

Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
Immunic announces enrollment of the first patient in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium for Post COVID Syndrome. Study aims to suppress EBV reactivation and fatigue symptoms

Clinical Trial Immunic Vidofludimus Calcium Phase 2 Post COVID Syndrome
BRIEF

published on 08/28/2024 at 12:35, 2 months 24 days ago

Immunic organise une journée de recherche et développement sur la sclérose en plaques et participe à des conférences scientifiques et d'investisseurs en septembre

Sclérose En Plaques Conférences Scientifiques Journée R&D Immunique Vidofludimus Calcique
BRIEF

published on 08/28/2024 at 12:35, 2 months 24 days ago

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September

Multiple Sclerosis Immunic Vidofludimus Calcium R&D Day Scientific Conferences
PRESS RELEASE

published on 08/28/2024 at 12:30, 2 months 24 days ago

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September
Immunic to host Multiple Sclerosis R&D Day & participate in conferences. Immunic, Inc. develops oral therapies for autoimmune diseases

Investor Conferences Multiple Sclerosis Immunic R&D Day Scientific Conferences
BRIEF

published on 08/08/2024 at 12:35, 3 months 13 days ago

Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Financial Results Biotechnology Clinical Trials Multiple Sclerosis Immunic
BRIEF

published on 08/08/2024 at 12:35, 3 months 13 days ago

Immunic, Inc. publie ses résultats financiers du deuxième trimestre 2024 et fait le point sur son entreprise

Résultats Financiers Biotechnologie Essais Cliniques Sclérose En Plaques Immunitaire
PRESS RELEASE

published on 08/08/2024 at 12:30, 3 months 13 days ago

Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Immunic, Inc. reports Q2 2024 financial results and corporate update, appoints new COO & strengthens BOD. Webcast on August 8. Ongoing trials remain on track

Financial Results Clinical Trials Corporate Update Immunic Inc. COO Appointment
BRIEF

published on 08/01/2024 at 12:35, 3 months 20 days ago

Immunic, Inc. annoncera ses résultats financiers pour le deuxième trimestre 2024 et fournira une mise à jour de l'entreprise

Biotechnologie Immunic, Inc. Webdiffusion Essais Cliniques Résultats Financiers Du Deuxième Trimestre
BRIEF

published on 08/01/2024 at 12:35, 3 months 20 days ago

Immunic, Inc. to Announce Financial Results for Q2 2024 and Provide Corporate Update

Biotechnology Clinical Trials Webcast Immunic, Inc. Q2 Financial Results
PRESS RELEASE

published on 08/01/2024 at 12:30, 3 months 20 days ago

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update
Immunic, Inc. to announce Q2 2024 financial results and corporate update on August 8, 2024, including webcast participation details. Company developing therapies for inflammatory diseases

Financial Results Webcast Immunic Inc. Q2 2024 Inflammatory Diseases

Published on 11/21/2024 at 16:01, 38 minutes ago

Career Certified Extends Its Investment in the Fast-Growing Architecture, Engineering, and Construction (AEC) Professionals Market with Acquisition of My Contractors License
Published on 11/21/2024 at 16:00, 39 minutes ago

Financial Independence Group Announces Exclusive Partnership With Power of Zero and Tax-Free Retirement Expert David McKnight
Published on 11/21/2024 at 16:00, 39 minutes ago

Wiz Acquires Dazz to Revolutionize Cloud Security Remediation
Published on 11/21/2024 at 16:00, 39 minutes ago

Isaac Ullatil Joins Wellstack Board of Directors
Published on 11/21/2024 at 15:30, 1 hour 9 minutes ago

CLS Health Opens New Comprehensive Care Clinic in Sugar Creek

View all ACCESSWIRE

Published on 11/21/2024 at 16:00, 39 minutes ago

Director/PDMR Shareholding
Published on 11/21/2024 at 15:41, 57 minutes ago

Edison issues report on Murray Income Trust (MUT)
Published on 11/21/2024 at 15:24, 1 hour 15 minutes ago

Form 8.3 - The Vanguard Group, Inc.: International Paper Company
Published on 11/21/2024 at 15:23, 1 hour 16 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Centamin plc
Published on 11/21/2024 at 15:22, 1 hour 17 minutes ago

Form 8.3 - The Vanguard Group, Inc.: TI Fluid Systems plc

View all EQS

Published on 11/21/2024 at 06:58, 9 hours 41 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 9 hours 41 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 9 hours 41 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 20 hours 31 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 21 hours 19 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE

News